Beta Drugs LtdQ1 FY26
Beta Drugs Ltd
Q1 FY26 Earnings Call Analysis
Management growth scorecard
Revenue
Category 2
Margin
Category 2
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030.
- →Export revenues are expected to grow at least 50% in the current year with a medium-term target of reaching INR 200-250 crores by FY28.
- →Exports are anticipated to contribute about 30% of total revenue by FY30.
- →The cosmetology and dermatology division aims for 30%-40% annual growth for the next 3-4 years.
- →The newly acquired Nivian IVF/fertility business is expected to grow at 30% annually over the next 3-4 years.
- →Beta plans to launch 20-25 new oncology products over the next 3-4 years to drive branded sales growth of 20%-25%.
- →CDMO business aims for steady growth of 5%-6% annually in the coming years.
- →Improvement in production capacities and new intermediate API plant commercialization is expected to enhance margins and growth.
Margin guidance
Category 2- →Beta Drugs aims to grow sales at 20% to 25% annually over the next 4 years, targeting INR850-900 crores revenue by 2030 (Page 15).
- →The company expects a doubling of sales from current levels in the next 4 years (Page 15).
- →EBITDA margins are expected to improve above 23%-24%, supported by growth in exports and branded sales (Page 5).
- →Export revenues are projected to grow substantially, with 50% growth expected in FY27 due to delayed tender awards being cleared (Page 15, 13).
- →The newly acquired Nivian fertility business consolidation from FY27 will add revenue, with an 18-19% EBITDA margin and 9-10% PAT margin (Page 6).
- →Capex plans for next 2 years are modest (INR 25 crores), implying leveraged growth from existing assets supporting INR700-800 crores peak revenues without major investment (Page 9).
- →Interest costs will reduce significantly post-debenture conversion in May 2026, aiding profitability (Page 9).
Sign up free to read the full earnings analysis
Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Beta Drugs Ltd and 1,400+ other companies.
Fundraise plans
Yes- No major debt increase is planned for FY27 and FY28; expected borrowings are modest with working capital utilization around INR7-10 crores and term loans close to INR20 crores.
- Compulsory convertible debentures (CCD) are set to convert to equity by May 2026, reducing interest expenses significantly.
- Capex requirements for the next two years are low (not more than INR25 crores), minimizing the need for new debt.
- Currently, there is around INR100 crores cash on hand, and management is open to acquisitions if opportunities arise, but no immediate plans or options are in hand.
- No explicit mention of upcoming equity fundraising; focus is on organic growth and strategic acquisitions if opportunities arise.
- Interest cost expected to reduce post CCD conversion, with normal bank interest rates around 7.5-8% on existing loans.
Overall, Beta Drugs does not anticipate substantial new fundraising through debt or equity in the near term.
Order book
Yes- →As of Q1 FY27, Beta Drugs has around 50% of export orders in hand for the upcoming quarter.
- →The company expects to fulfill existing orders and is also anticipating new orders and tenders.
- →Pending export tenders that were delayed and missed in FY26 have now been awarded in March 2026, with supplies starting from Q1 FY27.
- →These delayed tenders had an estimated revenue impact of INR 20-25 crores.
- →The company has laid strategies to focus on other high-margin products amid challenges in Platen sales.
- →Export orders for the current quarter are expected to be around INR 20-22 crores, with solid growth anticipated in subsequent quarters.
- →Overall, the order book visibility is healthy with orders in hand and an expectation of additional new tenders.
Capex plans
Yes- →Beta Drugs invested around INR45 crores last year across three plants, including land purchase for R&D and corporate office which was later dropped in favor of an office building adjacent to current facilities (Page 9).
- →The intermediate plant was acquired for INR9 crores with an additional investment of INR15-17 crores; this plant is expected to commercialize by end of this year (Page 9).
- →Total planned capex for the next two years is not expected to exceed INR25 crores, primarily towards the intermediate plant (Page 9).
- →No major capex planned beyond that, indicating stable capital expenditure outlook (Page 9).
- →The company is open to strategic acquisitions if exciting opportunities arise but currently has no options in hand (Page 6).
- →The intermediate plant is aimed at reducing dependency on imports and improving margins slightly by 1 to 1.5 basis points when commercialized (Pages 9-10).
How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Beta Drugs Ltd
Rev 2Mar 2
See full Pharmaceuticals & Biotechnology sector rankings
Unlock with ProWant more stocks like Beta Drugs Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio